1/12/2020 7:47:16 PM
Alnylam Reports Q4 Preliminary Global Net Product Revenues Of
$56 Mln
12/17/2019 7:05:36 AM
Alnylam Reports Positive Topline Results From ILLUMINATE-A Phase 3 Study Of Lumasiran
11/22/2019 7:07:15 AM
Alnylam Plans To Discuss Its Commercial And R&D Progress
11/19/2019 8:14:16 AM
Alnylam Accepts Applications For Second Annual Global Competitive Grants Program, Advocacy For Impact
10/31/2019 8:03:42 AM
Alnylam Pharma Q3 GAAP Loss Per Share $1.92; Non-GAAP Loss Per Share $1.50
10/10/2019 7:33:56 AM
Alnylam Files Marketing Authorization Of ONPATTRO In Brazil For Hereditary ATTR Amyloidosis With Polyneuropathy
9/13/2019 7:33:00 AM
Alnylam Presents New Results Demonstrating Significant Association Of V122I
9/2/2019 4:02:42 AM
Alnylam Provides Perspective On Positive Complete Results From ORION-11 Phase 3 Study Of Inclisiran
8/13/2019 7:33:29 AM
Ironwood Pharma, Alnylam Pharma Enter U.S. GI Disease Education And Promotional Agreement For Givosiran In AHP
8/6/2019 8:05:14 AM
Alnylam Pharma Q2 Loss Per Share $2.02 Vs Loss $1.63 Last Year
7/11/2019 8:32:59 AM
Alnylam Names Jeff Poulton EVP And CFO; Manmeet Soni To Resign